Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2000-03-03
2001-11-27
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S235100, C435S320100, C435S069100, C435S455000, C435S325000, C435S366000, C435S369000
Reexamination Certificate
active
06323031
ABSTRACT:
FIELD OF THE INVENTION
The object of the present invention are retroviral vectors (so-called lentiviral vectors) derived from SIVagm (AGM, African vervet monkey; Cercopithecus or Chlorocebus, respectively), methods for their preparation as well as their use for gene transfer into mammalian cells.
BACKGROUND OF THE INVENTION
The term “lentiviral vectors” or “SIVagm vectors” refers to infectious, but propagation-incompetent retroviruses capable of introducing genes into cells in the form of retroviral expression vectors (also called expression constructs or packaging-competent constructs). Lentiviruses refers to a group of retroviridae which following an infection of man, other primates, and mammals (e.g. sheep, cats) leads to a disease condition after a long incubation period. Gene transfer using retroviruses or lentiviruses, respectively, is also referred to as transduction. The gene transfer results in an integration of the expression vector into the cellular genome. Expression vectors include a packaging signal psi leading to incorporation of RNA of the expression vector into vector particles and to gene transfer. Therefore, “psi” refers to the retroviral packaging signal controlling efficient packaging of messenger RNA of the expression vector. Furthermore, the expression vector must be flanked by lentiviral LTR sequences (“long terminal repeats”) in order to enable correct transcription of the RNA of the expression vector into DNA and subsequent integration of the expression vector gene into the chromosomal DNA of the cell. Lentiviral gene transfer is advantageous because (i) generally a copy of the desired gene is transduced into cells, (ii) usually, the gene is transferred without mutations or rearrangements, (iii) stable incorporation into the chromosome occurs, and (iv) genes can also be transferred into non-proliferating cells.
It has been known to use lentiviral vectors on the basis of the human immunodeficiency virus type 1 (HIV-1), type 2 (HIV-2), and the simian immunodeficiency virus of the rhesus monkey (
Macaca mulatta
) for the transfer of particular genes into mammalian cells and also specifically into human cells. A particular advantage of lentiviral vectors is their ability to transduce also resting or non-dividing cells, respectively. These vectors are propagation-incompetent and merely go through one cycle of replication. Three components are required for the preparation of such vectors. Within a packaging cell, a psi-negative gag/pol gene of the original lentivirus, a psi-negative env gene which may be derived from lentiviruses or other viruses, and a psi-positive and therefore packaging-competent expression construct usually also derived from a lentivirus. The expression vector enables packaging into the retroviral vector and transfer by the retrovirus to transduce a coding and translation-competent region of the desired gene product into the target cell. Following transduction of the plasmids containing the gag/pol gene, the env gene, and the expression vector gene by transfection of the three respective DNAs into a suitable mammalian cell, a packaging cell is generated which releases retroviral vector particles into the cell supernatant which exclusively contain the expression construct, however, lacking the psi-negative gag/pol and env genes so that these are not introduced into the target cells.
The tropism of lentiviral vectors, i.e. the selection of the mammalian cells into which they are able to transduce the expression construct is determined by the env gene in the packaging cell used and, thus, by the env gene products present in the vector particles. The env gene of retroviruses among which e.g. the murine leukemia virus (MLV), several lentiviruses such as HIV, SIV, or FIV (“feline immunodeficiency virus”), but also EIAV (“equine infectious anemia virus”) or CIAV (“caprine infectious anemia virus”) are used in the formation of lentiviral vector particles is translated into envelope proteins, the transmembrane protein (TM) and the surface envelope protein (SU) forming the outer envelope of the lentiviral vector. To date, mainly the env gene products of the amphotropic MLV, the GaLV (“gibbon ape leukemia virus”) and the G protein of VSV (“vesicular stomatitis virus”; Burns et al., Proc. Natl. Acad. Sci. USA 90 (1993), 8033-8037) are used for gene transfer. They enable gene transfer into a wide variety of different mammalian cells and also in human cells. Particularly for selective gene transfer into human cells of a specific cell type, e.g. T cells or hematopoietic stem cells, the env gene products of the ecotropic, the amphotropic MLV or the spleen necrosis virus (SNV) are useful if they have been modified by introduction of domains of single chain antibodies (scFv, “single chain Fv”) or other ligands for cell surface proteins such as for example cytokins or growth factors.
To improve the transduction of various genes, retroviral vectors have been proposed in which the gag/pol gene of different lentiviruses such as HIV-1, HIV-2, SIVmac, FIV, or EIAV was used instead of the gag/pol gene of oncoretroviruses such as MLV. Therefore, it is an object of the present invention to provide improved lentiviral vectors (retroviral virus particles).
This object has been achieved by the claimed invention.
SUMMARY OF THE INVENTION
The present invention features an SIVagm vector that includes a viral core derived from simian immunodeficiency virus (SIVagm) of the African vervet monkey (Chlorocebus, formerly
Cercopithecus aethiops
) and a viral envelope derived from SIVagm or another virus. The viral envelope can be derived from human immunodeficiency virus 1 or 2 (HIV-1 or HIV-2, respectively), simian immunodeficiency virus
Cercopithecus aethiops
(SIVagm),
Cercopithecus mitis
(SIVsyk),
Papio sphinx
(SIVmnd),
Cercocebus atys
(SIVsm), or
Macaca nemestrina
(SIVmne). The viral envelope used can include an envelope of the murine ecotropic or amphotropic leukemia virus (MLV), the avian spleen necrosis virus (SNV), the “gibbon ape leukemia virus” (GaLV), or the porcine endogenous or porcine exogenous retrovirus (PERV). A particular advantage of lentiviral vectors derived from SIVagm is that, when SIVagm envelope proteins are used, no (or only a low amount of) antibodies, particularly neutralizing antibodies, are formed against the vector. This enables many applications that are impossible with other lentiviral vectors. On the other hand, the vectors of the invention can also be used in the presence of anti-HIV antibodies that do not (or only slightly) inhibit gene transfer with SIVagm vectors having a homologous SIVagm envelope. A further distinctive feature of SIVagm vectors is that using their genes they may be packaged and transduced into mammalian cells which would inhibit the formation of the corresponding vector particles derived from HIV or other lentiviruses. For example, genes for antibodies directed against HIV-1 reverse transcriptase or integrase (anti-rt scFv and anti-int scFv genes) may be packaged and used for gene transfer by means of SIVagm vectors, while the use of HIV vectors for such gene transfers is inefficient or of very low efficiency.
In one embodiment of the present invention, any cell is transfected with a psi-negative expression gene for gag and pol genes of SIVagm. Furthermore, the cell may be transfected with an expression construct comprising a psi packaging signal and the genetic information to be transduced into the target cell. The expression construct may be derived from SIVagm, SIVmac, or HIV, however, it must enable packaging and transcription in association with the use of the enzymatic gene products of the pol gene and the capsid gene products of the gag gene of SIVagm. Then, the cell is transfected with another expression gene containing the genetic information for foreign or own envelope proteins. The cell line thus prepared produces lentiviral SIVagm-derived vectors containing the genetic information to be transduced.
In a preferred embodiment, the human cell line 293T is transfected simultaneously with the SIVagm g
Bundesrepublik Deutschland letztvertreten durch den Prasidenten
Fish & Richardson P.C.
Guzo David
LandOfFree
Lentiviral vectors derived from SIVagm, methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lentiviral vectors derived from SIVagm, methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lentiviral vectors derived from SIVagm, methods for their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2595475